| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.16 | 0.0007 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | -0.18 | 0.001 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.16 | 0.002 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.098 | 0.004 |